CSTL Q1 2024 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q1 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$73M+73.6% YoY

Gross Profit

$59M81.0% margin

Operating Income

-$5M-7.5% margin

Net Income

-$3M-3.5% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+10.4%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$16M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$459M

Total Liabilities

$56M

Stockholders' Equity

$402M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$73M	$42M	+73.6%
Gross Profit	$59M	$32M	+85.5%
Operating Income	-$5M	-$32M	+82.6%
Net Income	-$3M	-$29M	+91.3%

Revenue Segments

Dermatologic

$59M100%